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Decitabine is a hypomethylating agent that irreversibly inhibits DNA methyltransferase I, inducing leukemic
differentiation and re-expression of epigenetically silenced putative tumor antigens. We assessed safety and
efﬁcacy of decitabine maintenance after allogeneic transplantation for acute myeloid leukemia (AML) and
myelodysplastic syndrome (MDS). Decitabine maintenance may help eradicate minimal residual disease,
decrease the incidence of graft-versus-host disease (GVHD), and facilitate a graft-versus-leukemia effect by
enhancing the effect of T regulatory lymphocytes. Patients with AML/MDS in complete remission (CR) after
allotransplantation started decitabine between day þ50 and þ100. We investigated 4 decitabine doses in
cohorts of 4 patients: 5, 7.5, 10, and 15 mg/m2/day  5 days every 6 weeks, for a maximum 8 cycles. The
maximum tolerated dose (MTD) was deﬁned as the maximum dose at which  25% of people experience
dose-limiting toxicities during the ﬁrst cycle of treatment. Twenty-four patients were enrolled and 22 were
evaluable. All 4 dose levels were completed and no MTD was reached. Overall, decitabine maintenance was
well tolerated. Grade 3 and 4 hematological toxicities were experienced by 75% of patients, including all
patients treated at the highest dose level. Nine patients completed all 8 cycles and 8 of them remain in CR.
Nine patients died from relapse (n ¼ 4), infectious complications (n ¼ 3), and GVHD (n ¼ 2). Most occurrences
of acute GVHD were mild and resolved without interruption of treatment; 1 patient died of acute gut GVHD.
Decitabine maintenance did not clearly impact the rate of chronic GVHD. Although there was a trend of
increased FOXP3 expression, results were not statistically signiﬁcant. In conclusion, decitabine maintenance is
associated with acceptable toxicities when given in the post-allotransplantation setting. Although the MTD
was not reached, the dose of 10 mg/m2 for 5 days every 6 weeks appeared to be the optimal dose rather than
15 mg/m2, where most hematological toxicities occurred.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION regimens, and better supportive care, resulting in improved
Allogeneic hematopoietic stem cell transplantation
(alloHSCT) is a potentially curative therapy for patients with
high-risk acute myeloid leukemia (AML) and myelodys-
plastic syndrome (MDS).
Over the past decade, we have witnessed signiﬁcant ad-
vances in therapeutic approaches for alloHSCT, including the
use of alternative stem cell sources, less toxic conditioningdgments on page 1768.
requests: Iskra Pusic, MD, Division of
tation and Leukemia Section, Washing-
Siteman Cancer Center, 660 South Euclid
is, MO 63110.
stl.edu (I. Pusic).
15.05.026
ty for Blood and Marrow Transplantation.overall survival (OS) [1-5]. However, disease relapse remains
the principal cause of treatment failure for these patients
[6-9]. The risk of relapse varies from 20% to 60%, depending
on the diagnosis and stage of the disease at the time of
transplantation, and outcomes of salvage treatments are
poor [10-12]. Median time to relapse after nonmyeloablative
alloHSCT is 3 to 6 months and somewhat longer after mye-
loablative alloHSCT. Therefore, early maintenance therapy,
directed at eliminating minimal residual disease and pro-
moting a graft-versus-leukemia (GVL) effect, could be an
effective method to improve outcomes after alloHSCT.
The concept of post-transplantationmaintenance therapy
with hypomethylating agents in AML and MDS has been
I. Pusic et al. / Biol Blood Marrow Transplant 21 (2015) 1761e17691762initially studied by investigators at MD Anderson Cancer
Center [13-15]. They showed that azacitidine (AZA) can
be safely administered to heavily pretreated post-
transplantation patients and may prolong event-free and
OS. In addition, recent studies have shown that AZA, fol-
lowed by donor lymphocyte infusion, is well tolerated when
administered for early AML/MDS relapse after alloHSCT
[16-18]. Decitabine (5-aza-20-deoxycytidine) is a hypome-
thylating agent that irreversibly inhibits DNA methyl-
transferase I (DNMT-1), leading to genome-wide global DNA
hypomethylation. Although AZA incorporates primarily into
RNA and to the lesser extent DNA, decitabine is more selec-
tive, reducing only DNA methylation. In addition, decitabine
is an approximately 5-fold more potent inhibitor of DNMT-1
than AZA is. Decitabine induces leukemic differentiation and
re-expression of tumor-associated genes that had been
epigenetically silenced [19]. At high doses, cells die from
apoptosis triggered by DNA synthesis arrest, and at low
doses, cells survive but change their gene expression proﬁle
to favor differentiation, reduced proliferation, and increased
apoptosis. In addition, maximum effects of DNA hypo-
methylation have been observed at low doses and with less
side-effects [20,21]. Decitabine has demonstrated activity in
a variety of hematological malignances, including AML, MDS,
and blast phase chronic myeloid leukemia [22-30]. It is
generally well tolerated, with the primary toxicity being
prolonged myelosuppression. Our group has demonstrated
that decitabine enhances FOXP3 expression and can convert
CD4þCD25FOXP3 T cells into CD4þCD25þFOXP3þ T regu-
latory cells (Tregs) [31,32]. Through their immunoregulatory
properties Tregs are thought to play an important role in
modulating graft-versus-host disease (GVHD) without
sacriﬁcing the beneﬁcial GVL effect [33,34]. In addition,
several other groups have demonstrated effects of DNA
hypomethylating agents on T cellemediated antitumor
activity [35-39]. These include increasing tumor-speciﬁc CD8
T cell responses by upregulating tumor antigen expression
on malignant cells and inducing expression of killer cell
immunoglobulinelike receptor in T cells, thereby enhancing
cytotoxic effector function of T cells against tumors. In
human studies, patients noted to have a higher relative fre-
quency of Tregs after HSCT had lower rate and severity
of GVHD, lower rate of nonrelapse mortality (NRM), and
equivalent relapse mortality [34].
Taken together, these studies provide a rationale for the
administration of decitabine after alloHSCT for AML and
MDS. We hypothesized that decitabine maintenance may
provide direct antileukemic effect both to eradicate minimal
residual disease and provide disease control by facilitating a
GVL effect. In addition, decitabine may decrease the inci-
dence of GVHD by enhancing the effect of Treg lymphocytes.
PATIENTS AND METHODS
This was a single-institution, open-label, prospective, dose-ﬁnding
study of low-dose decitabine as a maintenance therapy after alloHSCT. The
trial was approved by the institutional review board at the Washington
University School of Medicine and informed consent was obtained in
accordance with the Declaration of Helsinki. The trial was registered at
www.clinicaltrials.gov (NCT00986804). Eisai Inc. provided decitabine for all
enrolled patients.
Eligibility Criteria and Enrollment
Adults 18 years of age or older, with AML or MDS, who achieved a
complete remission (CR) after alloHSCT were enrolled in the study between
day þ50 and þ100 after alloHSCT. Exceptions were made for 3 patients who
were enrolled shortly after dayþ100: for 2 patients, dayþ100 fell during theweekend/holiday, and for 1 patient, who was already consented, lived far
away, and had transportation problems. CRwas deﬁned as< 5% blasts in the
bone marrow with a count of at least 200 nucleated cells, no blasts with
Auer rods, no extramedullary disease, absolute neutrophil count (ANC)
 1500/mL, platelet count 50,000/mL, and no blasts in the peripheral blood.
The higher threshold for ANC than that recommended by International
Working Group (IWG), was chosen in anticipation of neutropenia secondary
to decitabine and lower platelet threshold was allowed to facilitate enroll-
ment. No platelet transfusion within 7 days of enrollment or growth factor
support was allowed to meet those criteria. Other major eligibility criteria
included Eastern Cooperative Oncology Group performance status  2, no
grade 3 and 4 acute GVHD, no uncontrolled infection, creatinine < 1.5 
upper limit of normal (ULN), bilirubin  1.5  ULN, and hepatic enzymes 
2.5ULN. Bothmyeloablative and nonmyeloablative conditioning regimens
were allowed, and both related and unrelated donors were permitted using
either peripheral blood or bone marrow as a source of graft. Donors could be
mismatched at a single antigen at HLA-A, -B, or -DR locus, plus a single
antigen mismatch at HLA-C; 2-antigen mismatch at a single locus was not
allowed. Acute GVHD prophylaxis was according to the treating physician.
Treatment Plan
Decitabine was administered as an intravenous infusion for 5 consecu-
tive days every 6 weeks for up to 8 cycles. The study consisted of 5 escalating
dose levels, only 1 of which was open for accrual at a given time. The ﬁrst
cohort of 4 patients started decitabine at 5 mg/m2/day. In subsequent
cohorts, the dosewas escalated to 7.5,10, and 15mg/m2/day according to the
dose-limiting toxicity (DLT) experienced at the previous dose level. Deci-
tabine dose could be de-escalated to 2.5 mg/m2/day if a DLT were observed
in the ﬁrst cohort. There was an observation period of 42 days between
enrolling each subsequent cohort.
The primary goal was to determine themaximum tolerated dose (MTD) of
decitabine, deﬁned as the maximum dose at which  25% of patients
experience DLT during the ﬁrst cycle of treatment. DLT was deﬁned as (1)
ANC< 500/mL and/or platelet count< 30,000/mL sustained for 2 consecutive
weeks without platelet transfusions, (2) inability to achieve ANC  1000/mL
and platelet count  50,000/mL after a delay of the second cycle by a
maximum 2 weeks, or (3) grade 3 and 4 nonhematological toxicities related
to decitabine. Patients who met criteria for DLT started the second cycle at 1
level dose reduction. Patients with inadequate counts 6 weeks after a pre-
vious cycle had their next cycle delayed by maximum of 2 weeks. Each
cohort could contain 4 or 8 evaluable patients until a MTD or a dose of 15
mg/m2/day were reached. Patients with documented progressive disease
were removed from the study.
Dose Adjustments
Dose adjustments were made as follows: If no DLT were observed in any
of the 4 patients treated at the current dose-level, the current dose was
deemed acceptable and the study proceeded with dose escalation. If a DLT
were observed in 1 of 4 patients treated at current dose-level, then 4
additional patients were enrolled at same dose-level. If 1 of those 8 expe-
rienced a DLT, then the current dose was deemed acceptable and escalated;
if 2 or more of 8 patients experienced DLTs, then the current dose was
deemed over toxicity and the previous dose was considered MTD. If 2 or
more of 4 patients experienced a DLT, the current dose was deemed over
toxicity and the previous dose level was considered MTD.
Evaluation of Response
All patients completing the ﬁrst cycle of decitabine were included in the
safety and efﬁcacy assessment. History, physical exam, complete blood
count, and complete metabolic panel were performed at baseline and every
2 weeks thereafter. Bone marrow biopsy was performed at baseline, at cycle
3 day 1, and at cycle 8 day 42 (or at end of study for any reason). Acute and
chronic GVHD evaluation were performed every 2 cycles or sooner, if clin-
ically indicated. Chronic GVHD was diagnosed and graded according to the
National Institutes of Health Criteria [40]. Determination of relapse was
based on the peripheral blood, bone marrow biopsy, or evidence of new
extramedullary disease. Patients were followed for survival and relapse for 5
years.
Toxicity Assessment
All patients receiving at least 1 dose of decitabine were included in the
toxicity assessments. Adverse events were graded according to the National
Cancer Institute Common Toxicity Criteria, version 3.0. Serious adverse event
was deﬁned as any toxicity that met any of the following conditions:
resulted in death, was life threatening, required hospitalization, or resulted
in signiﬁcant disability or incapacity. Toxicity assessment was performed at
the beginning of each cycle.
Table 1
Patients’ Characteristics
Cohort (Dose) Patient No. Sex/Age, y Diagnosis and
Status at alloHSCT
Disease Risk Donor
Type
Conditioning
Regimen
Days from
alloHSCT to Dec
Chimerism at
Enrollment, %
1 (5 mg/m2) 1 M/62 AML-PD Phþ AML mMUD BU/CY 95 100
2 F/59 AML-PD Prior MF, trisomy 8, FLT3-ITDþ MRD BU/CY 62 Mixed
3 M/37 AML-CR1 Monosomy 7 MUD BU/CY 75 100
4 M/62 AML-PD Prior MDS, trisomy 19 MUD TBI/CY 95 Mixed
5 M/57 MDS Trisomy 8, 5q- MUD BU/CY 76 100
6 M/59 AML-CR2 t (8,21), CR2 MUD BU/CY 77 100
7 M/42 AML-CR1 Del 12/ETV6 mMUD BU/CY 115 100
8 M/52 MDS Del 5, Del 6 MUD BU/CY 90 100
9 M/58 AML-CR1 Complex cytogenetics MRD BU/CY 98 100
2 (7.5 mg/m2) 10 F/68 AML-CR1 Complex cytogenetics MRD FLU/BU 96 100
11 F/65 AML-CR1 FLT 3-ITD þ MUD TBI/CY 96 100
12 F/45 AML-CR1 Therapy-related AML mMRD BU/CY 98 100
13 M/63 AML-CR1 Prior MDS mMUD BU/CY 103 100
3 (10 mg/m2) 14 M/21 AML-CR1 FLT3-ITD þ MUD BU/CY 97 100
15 F/56 AML-CR1 Complex cytogenetics MUD BU/CY 87 100
16 M/62 MDS High-grade MDS MUD BU/CY 95 100
17 M/63 AML-CR1 Prior MDS MRD BU/CY 102 100
4 (15 mg/m2) 18 F/54 AML-CR2 CR2 MRD BU/CY 95 100
19 F/51 AML-CR1 MLL rearrangement MUD BU/CY 82 100
20 M/57 MDS Del 7 mMUD BU/CY 86 100
21 M/67 AML-CR1 Del 17p (p53) MUD FLU/BU 74 100
22 M/66 MDS High-grade MDS MRD BU/CY 100 100
Dec indicates decitabine; M, male, PD, persistent disease; Ph, Philadelphia chromosome; mMUD, mismatched unrelated donor; BU, busulfan; CY, cyclophos-
phamide; F, female; MF, myeloﬁbrosis; MRD, matched related donor; MUD, matched unrelated donor; TBI, total body irradiation; Del, deletion; Flu, ﬂudarabine;
mMRD, mismatched related donor; FLT3, FMS-like tyrosine kinase 3; MLL, mixed-lineage leukemia gene translocation.
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Peripheral blood samples to examine levels of lymphocyte populations
were obtained at baseline, immediately before administration of decitabine
on cycle 1 day 1 (C1D1) and cycle 3 day 1, immediately after administration
of decitabine on cycle 1 day 5 (C1D5) and cycle 3 day 5, and at the end of
study (EOS). Flow cytometry of peripheral blood was performed to examine
lymphocyte populations including CD3þCD4þ T cells, CD3þCD8þ T cells,
CD4þFOXP3þ Tregs, CD3CD19þ B cells, and CD3CD56þ natural killer (NK)
cells. The following antibodies were used: CD3 PerCP-Cy5.5 (OKT3,
eBioscience, San Diego, CA), CD4 PE (RPA-T4, BD Biosciences, Franklin
Lakes, NJ), CD4 APC-eFluor780 (RPA-T4, eBiosciences), CD8 APC (RPA-T8,
BD Biosciences), CD19 APC (HIB19, BD Biosciences), CD56 PE (B159, BD
Biosciences), CD45 FITC (HI30, BD Biosciences), and FOXP3 PE (236A/E7,
eBiosciences). To determine absolute numbers of these cells, Sphero
Accucount Fluorescent Particles (Spherotech, Lake Forest, IL) were used. To
measure DNA methylation in the FOXP3 locus, CD4þ T cells were isolated
from the cohort treated with the highest dose of decitabine (15 mg/m2/
day) using a Sony SY3200 cell sorter (Sony Biotechnology, San Jose, CA)
operated by the Siteman Cancer Center Flow Cytometry shared resource.
The purities of the cells were 90% or higher. Direct bisulﬁte modiﬁcation
from cells and pyrosequencing analysis were performed by EpigenDx
(Hopkinton, MA). A total of 16 CpGs were analyzed: 5 CpGs in 50 UTR region
(6278 to 6216 from ATG, Ensembl Transcript ID ENST00000376207),
2 CpGs in the human Treg speciﬁc demethylated region (TSDR) (2376
to 2371 from ATG), and 9 CpGs in the TSDR (2330 to 2263 from
ATG) [41-43].
Statistical Analysis
Demographic and clinical characteristics of patients, as well as out-
comes and length of follow-up, were listed for each patient. Preliminary
efﬁcacy was also assessed from pooled data of all cohorts. The endpoints
for efﬁcacy included relapse of the hematological malignancy, incidence
and severity of GVHD, as well as OS and disease-free survival (DFS). OS was
deﬁned as the time from transplantation to death from any cause, and
survivors were censored at the date of last contact. DFSwas deﬁned as time
from transplantation to relapse or death, whichever occurred ﬁrst. Those
patients alive and relapse free were censored at date of last contact.
Probabilities of OS and DFS were estimated using the Kaplan-Meier prod-
uct-limit method. The cumulative incidence of relapse was estimated using
Gray’s subdistribution method to account for the presence of competing
risk because of NRM [44]. Statistical analyses were performed using
statistical packages cmprsk (http://biowww.dfci.harvard.edu/wgray) for
competing risk analysis and SAS 9.2 (SAS Institutes, Cary, NC) for all other
analyses.RESULTS
Patient Characteristics
Between May 2010 and April 2014, 24 patients were
enrolled and treated on this study. Two patients failed to
complete the ﬁrst cycle of treatment because of early
relapse; they were replaced and excluded from all analyses
other than toxicity. The characteristics of 22 evaluable
patients are shown in Table 1. There were 15 males. Median
age was 59 years (range, 21 to 68). Seventeen patients had
AML and 5 hadMDS. Twenty patients receivedmyeloablative
conditioning (2 total body irradiationebased conditioning)
and 2 patients received nonmyeloablative conditioning. Six
patients received alloHSCT from 10/10 HLAematched
siblings, 1 from 8/10-mismatched sibling, 11 from 10/10-
matched unrelated donors, and 4 from mismatched unre-
lated donors. All patients received mobilized peripheral
blood stem cells as the graft source and methotrexate and
tacrolimus as GVHD prophylaxis. All patients were in CR at
the time of enrollment. The median time from alloHSCT to
start of decitabine was 95 days (range, 62 to 115).
Dosing of Decitabine
Four patients were initially enrolled in cohort 1 (5mg/m2/
day) (Figure 1). One patient experienced a hematological DLT
and, therefore, 4 additional patients were added to expand
that cohort. None of the additional patients experienced a
DLT. One patient was replaced as he failed to receive all cycle
1 doses because of noncompliance; however, this patient
received subsequent cycles and remains evaluable for all
assessments besides MTD. Four patients were enrolled in
cohort 2 (7.5 mg/m2/day). One patient relapsed before
completing cycle 1 and was replaced. No DLTs were observed
in that cohort; therefore, 4 patients were enrolled in cohort 3
(10 mg/m2/day). None of those patients experienced a DLT
and 4 patients were enrolled in cohort 4 (15 mg/m2/day).
There were no DLTs at this dose level; however, 2 patients
Figure 1. Cohorts’ characteristics.
I. Pusic et al. / Biol Blood Marrow Transplant 21 (2015) 1761e17691764were replaced. One patient was replaced because of the early
relapse, before completing cycle 1. The other replaced patient
was deemed nonevaluable for DLT because hemissed several
laboratory data points and received growth factors for neu-
tropenia during the ﬁrst cycle; his decitabine dose was
reduced to 10 mg/m2/day and he completed the remaining
cycles at that dose. In summary, as only 1 patient met the
criteria for DLT, the MTD was not established.
Response and Mortality
Themedian number of cycles completedwas 5 (range,1 to
8). The causes for early discontinuationwere: toxicity (n¼ 5),
relapse (n¼ 3), new-onset severe gut GVHD (n¼ 1), physician
discretion (n ¼ 1), noncompliance (n ¼ 2), and consent with-
drawal (n¼ 1) (Table 2). Nine of 22 patients (41%) completed 8
cycles of decitabine and all of them are alive: 8 patients are in
CR and 1 patient developed central nervous system (CNS)
relapse and leukemia cutis 1 year after completing decitabine
maintenance and underwent a second alloHSCT. The remain-
ing13patients discontinueddecitabinebefore cycle 8 andonly
4 are alive: 3 patients are in CR and 1 patient developed CNS
relapse and underwent a second alloHSCT. Overall, 11 of 22
evaluable patients are alive in CR with full donor chimerism
(50%) and an additional 2 patients are alive after second
alloHSCT for CNS/extramedullary relapse.
After a median follow up of 26.7 months (range, 3.4 to
49.1) 6 patients relapsed and 9 died. All of the 6 patients who
relapsed had high-risk disease (3 underwent transplantation
with persistent disease, 1 had mixed-lineage leukemia gene
translocation (MLL) rearrangement, 1 had FMS-like tyrosine
kinase 3 (FLT3) mutation, and 1 had ETV6 gene ampliﬁcation
with persistent dysplasia after induction chemotherapy).
Only 1 of the relapsed patients had evidence of mild acute
GVHD. The 2-year OS and DFS were 56% (95% conﬁdence
interval [CI], 38% to 83%) and 48% (95% CI, 30% to 75%),
respectively (Figure 2). After adjusting for competing risk of
NRM, the 2-year cumulative incidence of relapse was 28%
(95% CI, 8% to 48%). Causes of death included relapse (n ¼ 4),
infectious complications (n ¼ 3), and GVHD (n ¼ 2; 1 from
acute gut GVHD, 1 from chronic lung GVHD). Among 6 pa-
tients who relapsed, 2 are alive after second alloHSCT and 4
died from their disease. Only 1 of the relapsed patients
completed all 8 cycles of decitabine; others received 1 to 4
cycles. Pretransplantation conditioning chemotherapy did
not appear to affect the results.Acute and Chronic GVHD
Five patients had resolving grade I and II classic acute
GVHD at the time of starting the study, and all of those
completely resolved while on decitabine, with taper of ste-
roids. One patient developed stage I gut GVHD during the
second cycle of decitabine that completely resolved after a
brief course of high-dose steroids with rapid taper, and
another patient developed stage IV gut GVHD coinciding
with the ﬁrst cycle of decitabine, requiring high-dose ste-
roids, that also completely resolved while on decitabine. One
patient developed stage IV gut GVHD immediately after the
ﬁrst cycle, was taken off the study, and eventually died from
progressive acute gut GVHD. One patient had late-onset
acute gastrointestinal (GI) GVHD that resolved.
Among 9 patients who completed all cycles of decitabine,
5 have developed chronic GVHD: 2 have severe and 3 pa-
tients have moderate chronic GVHD (Table 3). Among 13
patients who discontinued decitabine earlier, 10 are at risk
for chronic GVHD (2 patients died of early relapse and 1
patient died from acute gut GVHD). Seven of those 10 pa-
tients have developed chronic GVHD: 5 have severe chronic
GVHD (1 with features of overlap syndrome) and 2 have
moderate.
Toxicity Assessment
All 24 patients enrolled on the study were assessed for
toxicity. Generally, study treatments were well tolerated
(Table 4). Grade 3 and 4 hematological toxicities were
experienced by 18 of 24 patients (75%), including all 6 pa-
tients treated at the 15 mg/m2/day dose level. However,
typically hematological toxicities resolved quickly between
treatment cycles and accounted for very few treatment
delays. The only frequently occurring grade 3 and 4 non-
hematological toxicities were infections, which occurred in 8
of 24 patients (33%). Five patients discontinued the study
because of the toxicities: 2 of them for infection, 1 for neu-
tropenia, 1 for bowel obstruction, and 1 for fatigue. Among 3
patients who discontinued decitabine because of infections,
only 1 was neutropenic when infection developed.
Correlative Studies
We examined the effect of decitabine on lymphocyte
subpopulations, such as T cells, B cells, NK cells, and Tregs, in
all the patient samples, using ﬂow cytometry (Figures 3
and 4). Although we observed a trend toward increase of
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Figure 2. (A) Disease-free survival (DFS) and overall survival (OS). (B) Relapse
and non-relapse mortality.
I. Pusic et al. / Biol Blood Marrow Transplant 21 (2015) 1761e1769 1765Tregs after decitabine treatment, the difference was not
statistically signiﬁcant. In addition, a total of 16 CpG sites of
the FOXP3 locus in CD4þ T cells isolated from the cohort
treated with the highest dose of decitabine (15 mg/m2/day)
were analyzed, as described in Methods. The gene structure
of the FOXP3 locus is presented in Supplemental Figure 1. As
shown in Figure 5, we found that there is no statistically
signiﬁcant difference in the degree of DNAmethylation in the
FOXP3 locus before (C1D1 and cycle 3 day 1) and after (C1D5
and cycle 3 day 5) treatment and EOS, even though there was
a trend toward decrease in DNA methylation in cycle 1. C1D5
sample of patient S101 shows a decrease in DNAmethylation
when compared with C1D1 sample of the same patient.
Accordingly, its FOXP3 expression is higher than that of C1D1
sample (15.7% versus 11.8% FOXP3þ Tregs among CD4þ
T cells). All of these data indicate that our DNA methylation
data is consistent with the FOXP3 protein expression data.
Interestingly, we found that NK cells and CD8 Tcells aremore
sensitive to decitabine treatment in vivo with a consistent
quantitative decrease in these subsets after treatment,Table 3
GVHD Rates
GVHD Type No. with GVHD/No. at risk
Classic acute GVHD
Grade I-II 6/22
Grade III-IV GI 2/22
Late-onset acute GVHD 1/22
Chronic GVHD
Moderate
Pt completed 8 cycles 3/9
Pt completed < 8 cycles 2/10
Severe
Patient completed 8 cycles 2/9
Patient completed < 8 cycles 5/10*
* One of these 5 patients had overlap features of GVHD.
Table 4
Grade 3 and 4 Adverse Events
Event Grade
Anemia 3
Lymphopenia 2
Neutropenia 11
Thrombocytopenia 13
Hypotension 1
Pain, not speciﬁed 2
Diarrhea 1
SGOT (AST) 1
SGPT (ALT) 2
Infection/sepsis 8
Hypokalemia 1
Hyponatremia 1
Neuropathy 2
Dyspnea 1
Renal failure 1
SGOT indicates serum glutamic oxaloacetic transaminase; AST, aspartate
aminotransferase; SGPT, serum glutamic pyruvic transaminase; ALT, alanine
aminotransferase.
I. Pusic et al. / Biol Blood Marrow Transplant 21 (2015) 1761e17691766whereas CD4 T cells were relatively resistant to decitabine
treatment (Figures 3 and 4). The CD4 T cell number at EOS in
the 5 mg/m2/day cohort is higher than that at cycle 3 day 1.
The explanation for this observation is unknown and may
simply represent a more rapid recovery of CD4 T cells
compared to other T and NK cells after treatment.DISCUSSION
Disease recurrence after alloHSCT is the major cause of
treatment failure for patients with AML and MDS. Treatment
options for those patients are limited, responses poor, and
prognosis dismal. Because most of relapses occur in the ﬁrst
year after alloHSCT, preventive maintenance therapy should
be considered early in the post-transplantation course. De
Lima et al. ﬁrst described that AZA maintenance after
reduced-intensity alloHSCT for high-risk AML and MDS is
well tolerated and may prolong event-free and OS [13].
In this study, we examined the toxicity and responses to
low-dose decitabine as amaintenance therapy after alloHSCT
for patients with AML and MDS. To our knowledge, this is
the ﬁrst report of decitabine use in this setting. We haveFigure 3. Effect of decitabine on the frequency of Tregs, CD4 T cells, CD8 T cells, B cells
C1D5: cycle 1 day 5; C3D1: cycle 3 day 1; C3D5: cycle 3 day 5; END: end of study).demonstrated that decitabine can be given safely in the
outpatient setting to this group of post-alloHSCT patients.
Approximately 67% of our patients were able to receive at
least 4 cycles of decitabine and 41% received all 8 cycles. Main
DLT associated with decitabine use is myelosuppression [45].
The interval between cycles of 6 weeks rather than 4 weeks,
as commonly used for treatment of AML and MDS, was
chosen to facilitate count recovery. Several patients experi-
enced neutropenia and 1 of these qualiﬁed as DLT. Interest-
ingly, that patient relapsed 1 month later and it is possible
that the neutropenia in this patient was because of the early
relapse rather than a direct effect of decitabine.
All patients treated at the highest dose level (15 mg/m2/
day) experienced grade 3 or 4 hematological toxicities, none
qualifying for DLT. However, 1 patient from the last cohort
was discontinued after 4 cycles because of neutropenia
and the other required growth factor support. Therefore,
although no formal MTDwas reached: 10 mg/m2/daymay be
a more optimal and better tolerated dose for decitabine
maintenance in post-alloHSCT setting.
Three patients were discontinued from the study because
of relapse. All of them had high-risk disease and 2, in retro-
spect, already had early signs of relapse at the time of
enrollment (manifested as mixed chimerism and evidence of
multilineage dysplasia). Three additional patients, also with
high-risk disease, relapsed later, after being off decitabine.
Interestingly, only 1 patient who completed all 8 cycles of
decitabine relapsed. Longer administration of decitabine was
associated with prolonged OS and DFS.
Although decitabine could have been started between
day þ50 and þ100 after transplantation, the majority of
patients started close to day þ100. The study required bone
marrow biopsy within 2 weeks of starting decitabine.
In some instances, treating physicians were waiting for the
“standard-of-care” 3-month post-alloHSCT biopsy, rather
than obtaining the “study” biopsy earlier. Many of those
patients had blood counts adequate to start decitabine closer
to dayþ50 and, in retrospect, should have been biopsied and,
if eligible, enrolled.
Because most of our patients started decitabine around
day þ100 after alloHSCT, it is difﬁcult to determine the effect, and NK cells in the peripheral blood at stated time points (C1D1: cycle 1 day 1;
Figure 4. Effect of decitabine on the absolute number of Tregs, CD4 T cells, CD8 T cells, B cells, and NK cells in the peripheral blood and stated time points (C1D1: cycle
1 day 1; C1D5: cycle 1 day 5; C3D1: cycle 3 day 1; C3D5: cycle 3 day 5; END: end of study).
I. Pusic et al. / Biol Blood Marrow Transplant 21 (2015) 1761e1769 1767of decitabine on incidence of acute GVHD. Several patients
had grade I or II acute GVHD at the time of starting decita-
bine, which completely resolved and 1 patient had biopsy-
proven grade IV gut GVHD that started during the ﬁrst
week of decitabine therapy and completely resolved. How-
ever, 1 additional patient died from grade IV gut GVHD
developing after the ﬁrst cycle of decitabine. Decitabine
maintenance did not clearly impact the rate of chronic
GVHD; however, lack of comparison in this early phase study
precludes any further conclusion. Although the severity of
chronic GVHD appears to be lower in the group that
completed all 8 cycles of decitabine, this is merely the
observation; there were too few patients to suggest corre-
lation between decitabine and chronic GVHD severity. Earlier
post-transplantation initiation of decitabine might have a
greater impact on the incidence of GVHD. This is another
reason to support, for future studies, the use of lowerFigure 5. DNA methylation status at the FOXP3 locus of cohort 4 (15 mg/m2/days). Sho
each patient in cohort 4 (patients 18-22). Pt indicates patient; C, cycle; D, day.decitabine dose of 10 mg/m2 that should be better tolerated
and likely result in fewer hematological toxicities and in-
fectious complications.
Goodyear et al. used AZA maintenance after
alemtuzumab-containing reduced-intensity alloHSCT, con-
ﬁrming the tolerability of AZA in the post-transplantation
setting [35]. They observed increased number of Tregs
within ﬁrst 3 months after transplantation and relatively low
incidence of acute and chronic GVHD. However, important
differences between their study and ours are that they star-
ted AZA earlier in post-transplantation course and their
patients all received alemtuzumab-containing reduced-
intensity conditioning. Although we observed a trend of
increased FOXP3 expression, results were not statistically
signiﬁcant. There are several possible explanations for why
we did not observed an increase in FOXP3 expression. First,
we only examined peripheral blood. Considering that mostwn are means and standard deviations of DNA methylation status of 16 CpGs of
I. Pusic et al. / Biol Blood Marrow Transplant 21 (2015) 1761e17691768alloreactive T cells trafﬁc to GVHD-target organs, it might be
possible that those alloreactive T cells converted into FOXP3-
expressing T cells might be differentially localized in the
GVHD-target organs instead of the peripheral blood. Thus, it
might have been more informative to examine Tregs and T
cell subsets from GVHD target organs (skin, liver, and GI
tract) and not the peripheral blood. Second, decitabine needs
to incorporate into replicating DNA to block DNMT-1.
Therefore, unless alloreactive T cells are actively prolifer-
ating, the degree of incorporation of decitabine into DNA
would be limited, thereby minimizing conversion of allor-
eactive T cells into suppressive FOXP3 expressing Tregs.
Because decitabine maintenance was not performed imme-
diately after T cell infusion (stem cell transplantation) and
was performed in the context of standard GVHD prophylaxis
(calcineurin inhibitors) that also limit T cell proliferation and
viability, it is possible that the optimal effect of decitabine on
GVHD and FOXP3 expression was not realized in this study.
Finally, it is also possible that the doses of decitabine tested
in this study are not optimal to convert alloreactive T cells
in vivo into Tregs, although they might be optimal for
reduction of GVHD and maintenance of GVL. Decitabine does
appear to reduce the numbers of NK cells and CD8 T cells
while maintaining a relatively low rate of leukemia relapse,
suggesting possible direct antileukemia effect of decitabine
in vivo and increase of tumor-speciﬁc CD8 T cells responses.
In conclusion, low-dose decitabine maintenance is asso-
ciated with acceptable toxicities when given in the post-
alloHSCT setting. Although MTD was not reached, the dose
of 10 mg/m2 for 5 days every 6 weeks appears to be the
optimal dose rather than 15 mg/m2. Starting decitabine
closer to the stem cell and T cell infusion, when T cells are
rapidly expanding in allogeneic stem cell transplant
recipients, could potentially be more efﬁcacious in limiting
GVHD. This study provides essential data for subsequent
studies of decitabine maintenance. The availability of oral
hypomethylating agents might make this approach of post-
transplantation maintenance even more attractive.ACKNOWLEDGMENTS
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